Literature DB >> 27578915

Relationship between prostate volume changes and treatment duration of neoadjuvant androgen deprivation during intensity-modulated radiation therapy for Japanese patients with prostate cancer.

Masashi Tomida1, Kuniyasu Okudaira2, Takeshi Kamomae3, Hiroshi Oguchi4, Yoshikazu Miyake2, Kazuo Yoneda2, Yoshiyuki Itoh3.   

Abstract

The application of neoadjuvant androgen deprivation (NAD) in prostate cancer leads to a reduction in prostate volume, and the trends in volume reduction differ according to the treatment duration of NAD. A reduction in volume during external beam radiation therapy may lead to the exposure of normal tissues to an unexpected dose. In fact, prostate volume reductions have primarily been reported in European and American institutions. Although the prostate volume of Japanese patients is known to be small, the trends in prostate volume change during radiation therapy remain unclear. In the present study, we aimed to evaluate the changes in prostate volume of Japanese patients during intensity-modulated radiation therapy (IMRT) with NAD. Nineteen Japanese patients with prostate cancer underwent IMRT with NAD. Kilovoltage computed tomography (CT) images were obtained for treatment planning and verification of the treatment position for each treatment fraction. The patients were divided into 3 groups based on the duration of NAD, as follows: NAD < 3 months (short NAD: S-NAD), 3 months ≤ NAD < 6 months (middle NAD: M-NAD), and NAD ≥ 6 months (long NAD: L-NAD). The prostate volume reductions at the 36th treatment fraction, relative to the planning CT, were 7.8%, 2.0%, and 1.7% for the S-NAD, M-NAD, and L-NAD groups, respectively. Prostate volume shrunk greater in the S-NAD group than in the M-NAD and L-NAD groups; this finding was consistent with those of previous studies. The prostate volume changes in Japanese patients were smaller compared to those in European and American patients.

Entities:  

Keywords:  IGRT; IMRT; Japanese patients; neoadjuvant androgen deprivation; prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 27578915      PMCID: PMC4995277     

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  32 in total

1.  The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.

Authors:  C Onal; E Topkan; E Efe; M Yavuz; G Arslan; A Yavuz
Journal:  Br J Radiol       Date:  2009-07-06       Impact factor: 3.039

2.  Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries.

Authors:  N Masumori; T Tsukamoto; Y Kumamoto; H Miyake; T Rhodes; C J Girman; H A Guess; S J Jacobsen; M M Lieber
Journal:  J Urol       Date:  1996-04       Impact factor: 7.450

3.  NCCN clinical practice guidelines in oncology: prostate cancer.

Authors:  James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

4.  Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

Authors:  James W Denham; Allison Steigler; David S Lamb; David Joseph; Sandra Turner; John Matthews; Chris Atkinson; John North; David Christie; Nigel A Spry; Keen-Hun Tai; Chris Wynne; Catherine D'Este
Journal:  Lancet Oncol       Date:  2011-05       Impact factor: 41.316

5.  Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation.

Authors:  J D Forman; R Kumar; G Haas; J Montie; A T Porter; C F Mesina
Journal:  Cancer Invest       Date:  1995       Impact factor: 2.176

6.  Ethnicity and migration as determinants of human prostate size.

Authors:  B Jin; L Turner; Z Zhou; E L Zhou; D J Handelsman
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

7.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

8.  Changes of prostate gland volume with and without androgen deprivation after intensity modulated radiotherapy - A follow-up study.

Authors:  Christian M Zechmann; Khurram Aftab; Bernd Didinger; Frederik L Giesel; Patrik Zamecnik; Christian Thieke; Jurgen J Fütterer; Annette Kopp-Schneider; Hans-Ulrich Kauczor; Stefan Delorme
Journal:  Radiother Oncol       Date:  2008-10-22       Impact factor: 6.280

9.  Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy.

Authors:  David Palma; Emily Vollans; Kerry James; Sandy Nakano; Vitali Moiseenko; Richard Shaffer; Michael McKenzie; James Morris; Karl Otto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-05-01       Impact factor: 7.038

10.  The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer.

Authors:  F E Yang; G T Chen; P Ray; F Vaida; P Chiru; R J Hamilton; D Spelbring; M Abellera; S Vijayakumar
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-12-01       Impact factor: 7.038

View more
  1 in total

1.  Clinical usefulness of MLCs in robotic radiosurgery systems for prostate SBRT.

Authors:  Masashi Tomida; Takeshi Kamomae; Junji Suzuki; Yoichi Ohashi; Yoshiyuki Itoh; Hiroshi Oguchi; Takahito Okuda
Journal:  J Appl Clin Med Phys       Date:  2017-07-10       Impact factor: 2.102

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.